Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HIF1A antisense RNA 3 (HIF1A-AS3) is a long non-coding RNA (lncRNA) transcribed from the 3′ region of the HIF1A locus. It does not encode a protein but is a regulatory RNA that modulates the expression and activity of HIF1A mRNA and HIF-1α protein, a master regulator of cellular responses to hypoxia. HIF1A-AS3 positively regulates HIF1A expression in some cell types and is required for optimal HIF-1α-mediated transcription and glycolytic responses, especially under low oxygen or high glucose conditions. Functionally, it acts partly through interactions with protein partners such as PKM2 (pyruvate kinase M2) and PHD3 (prolyl hydroxylase 3), facilitating their association and nuclear translocation, which enhances HIF-1α transcriptional programs. HIF1A-AS3 expression is upregulated under hypoxia and in certain cancers, correlating with aggressive phenotypes and worse patient outcomes. Experimental knockdown of HIF1A-AS3 reduces HIF1A mRNA and protein expression, and disrupts hypoxia signaling, making it a candidate therapeutic target for nucleic acid-based approaches in cancer and other hypoxia-associated pathologies
For experimental drugs/therapies in research: Antisense or RNA interference-mediated knockdown reduces HIF1A-AS3, decreasing HIF1A mRNA and protein and downstream HIF-1α-mediated transcription
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HIF1A antisense RNA 3 (HIF1A-AS3).